Viking Therapeutics Inc (NASDAQ:VKTX) shares are trading lower by 10.9% to $63.95 Monday afternoon, despite a lack of company-specific news for the session.

The stock experienced marked strength in February after the company announced the Phase 2 VENTURE trial successfully achieved its primary endpoint and all secondary endpoints. The stock has also experienced volatility in recent sessions after the company announced its public offering of 6.471 million common shares at $85 per share.

Is VKTX A Good Stock To Buy?

An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages – like Viking Therapeutics's page for example – there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.

These are known as capital allocation programs. Viking Therapeutics does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's dividend calendar for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.

For example, if you're looking to earn an annualized return of 15.87%, you'll need to buy a share of Ellington Residential by the Mar. 27, 2024. Once done, you can expect to receive a nominal payout of $0.08 on Apr. 25, 2024.

Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on Viking Therapeutics will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.

According to data from Benzinga Pro, VKTX has a 52-week high of $99.41 and a 52-week low of $8.28.